Core Viewpoint - The restructuring of *ST Meigu (000615.SZ) is a focal point for the market, with the company announcing the reappointment of Zhongshang Zhonghuan Accounting Firm as its auditor for the 2025 fiscal year, pending approval from a temporary shareholders' meeting [2] Restructuring Plan - *ST Meigu has revealed details of its restructuring plan, identifying Hubei Jiuzhou Industrial Park Operation Management Co., Ltd. and Tianjin Xinmeitongcheng Equity Investment Partnership as key investors, along with six financial investors [4] - The restructuring plan involves a capital increase of approximately 1.024 billion shares, raising the total share capital to 1.787 billion shares, based on a ratio of 13.4278 shares for every 10 shares held [4] - The newly issued shares will be used primarily for three purposes: resolving related guarantee issues, compensating creditors with shares, and attracting restructuring investors [4] Financial Investment - Approximately 860 million shares will be allocated to attract restructuring investors, with a total investment amount of 1.536 billion yuan, where Hubei Jiuzhou will contribute 706 million yuan, accounting for nearly 46% of the total [4][5] Business Strategy Post-Reconstruction - After the restructuring, *ST Meigu plans to leverage the funds and resources from industrial investors to strengthen its existing beauty and health services while expanding into related businesses and enhancing its health industry chain [6] - The company aims to acquire quality assets related to its main business through retained funds and share issuance post-restructuring [7] Medical Aesthetics Focus - *ST Meigu's core asset remains in the medical aesthetics sector, having entered this market in 2021 with a significant acquisition of a 55% stake in Zhejiang Liantianmei for 697 million yuan [7] - The company has established strategic partnerships with various entities in the medical aesthetics field, although it faced challenges due to the downturn in the real estate sector, leading to continuous losses and financial distress [7][8] Potential Control Change - If the restructuring is successful, Jiuzhou Tong may become the controlling shareholder of *ST Meigu, as it has been actively investing in the medical aesthetics sector since 2016 [8] - Jiuzhou Tong's medical aesthetics business has shown significant growth, with sales revenue reaching 851 million yuan in 2024, a 120.47% increase year-on-year, and 904 million yuan in the first three quarters of the current year, up 45.84% [8][9]

Core Insights - The medical beauty sector experienced a decline of 0.65% on December 2, with Huaxi Biological leading the drop [1] - The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1] Sector Performance - The closing prices and performance of key stocks in the medical beauty sector are as follows: - Jinbo Biological: Closed at 223.43, up 2.42% with a trading volume of 11,300 hands and a transaction amount of 253 million [1] - *ST Meigu: Closed at 4.17, up 0.97% with a trading volume of 91,900 hands and a transaction amount of 37.83 million [1] - Aimeike: Closed at 145.06, down 0.64% with a trading volume of 16,000 hands and a transaction amount of 233 million [1] - Huaxi Biological: Closed at 46.57, down 0.89% with a trading volume of 20,600 hands and a transaction amount of 96.12 million [1] Capital Flow - The medical beauty sector saw a net outflow of 1.145 million from main funds, while retail investors had a net inflow of 1.233 million [1] - Detailed capital flow for key stocks is as follows: - Jinbo Biological: Main funds net inflow of 25.696 million, retail net inflow of 636,300 [2] - Huaxi Biological: Main funds net inflow of 4.2399 million, retail net inflow of 939,100 [2] - *ST Meigu: Main funds net inflow of 857,200, retail net inflow of 2.3685 million [2] - Aimeike: Main funds net outflow of 6.2421 million, retail net inflow of 9.0204 million [2]

Group 1 - The core viewpoint of the article highlights that *ST Meigu (SZ 000615) held its 29th meeting of the 11th Board of Directors on December 1, 2025, to review the proposal for the reappointment of the auditing institution for the fiscal year 2025 [1] - For the first half of 2025, the revenue composition of *ST Meigu shows that medical beauty services accounted for 57.47%, bio-based fibers accounted for 38.54%, and other services accounted for 3.99% [1] - As of the time of reporting, *ST Meigu has a market capitalization of 3.2 billion yuan [1]

证券代码：000615 证券简称：*ST美谷 公告编号：2025-104 奥园美谷科技股份有限公司 关于续聘 2025 年度审计机构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1．基本信息 （1）机构名称：中审众环会计师事务所（特殊普通合伙） （2）成立日期：中审众环始创于 1987 年，是全国首批取得国家批准具有从 事证券、期货相关业务资格及金融业务审计资格的大型会计师事务所之一。根据 财政部、证监会发布的从事证券服务业务会计师事务所备案名单，具备股份有限 公司发行股份、债券审计机构的资格。2013 年 11 月，按照国家财政部等有关要 求转制为特殊普通合伙制。 （3）组织形式：特殊普通合伙企业 （4）注册地址：湖北省武汉市武昌区水果湖街道中北路 166 号长江产业大 厦 17-18 层； （5）首席合伙人：石文先 奥园美谷科技股份有限公司（以下简称"公司"）2024 年度审计意见类型 为带持续经营重大不确定性段落的无保留意见。 公司于 2025 年 12 月 1 日召开的第十一届董事 ...

经公司第十一届董事会审计委员会审议表决一致同意后，董事会审议同意续 聘中审众环会计师事务所（特殊普通合伙）为公司 2025 年度审计机构，负责公 司 2025 年度财务报告及内部控制等审计工作。 董事会提请公司股东会授权公司管理层根据 2025 年度具体审计要求和审计 范围，参考 2024 年度的审计要求、审计范围及相应费用，结合市场价格水平由 双方协商确定审计费用。 本议案尚需提交公司临时股东会审议。 具 体 内 容 详 见 与 本 公 告 同 日 刊 登 在 《 证 券 时 报 》 和 巨 潮 资 讯 网 （www.cninfo.com.cn）的《关于续聘 2025 年度审计机构的公告》。 表决结果：9 票同意，0 票反对，0 票弃权。 证券代码：000615 证券简称：*ST美谷 公告编号：2025-103 奥园美谷科技股份有限公司 第十一届董事会第二十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 奥园美谷科技股份有限公司（以下简称"公司"）第十一届董事会第二十九 次会议通知于2025年11月27日以电子邮件方式通知公司全体董事，会议 ...

Core Viewpoint - The medical beauty sector experienced a slight increase of 0.08% on December 1, with Ai Meike leading the gains, while the overall market indices also showed positive performance [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3914.01, up by 0.65% [1] - The Shenzhen Component Index closed at 13146.72, up by 1.25% [1] Group 2: Medical Beauty Sector Stocks - Ai Meike (300896) closed at 146.00, with a gain of 0.43% and a trading volume of 19,900 lots, amounting to a transaction value of 289 million yuan [1] - Jinbo Biological (920982) closed at 218.15, with a gain of 0.41% and a trading volume of 4,509.52 lots, amounting to a transaction value of 98.26 million yuan [1] - Huaxi Biological (688363) closed at 66.99, remaining unchanged with a trading volume of 26,300 lots, amounting to a transaction value of 124 million yuan [1] - *ST Meigu (000615) closed at 4.13, down by 2.59% with a trading volume of 135,700 lots, amounting to a transaction value of 56.69 million yuan [1] Group 3: Capital Flow - The medical beauty sector saw a net outflow of 15.754 million yuan from institutional funds and a net outflow of 7.922 million yuan from speculative funds, while retail investors contributed a net inflow of 23.676 million yuan [1]

Core Viewpoint - *ST Meigu's restructuring plan involves a significant capital increase through the conversion of capital reserves into shares, aimed at addressing financial difficulties and attracting new investors [1] Group 1: Restructuring Plan Details - The restructuring plan will increase the total share capital of *ST Meigu from 762,979,719 shares to 1,787,492,693 shares by issuing an additional 1,024,512,974 shares at a ratio of 13.4278 shares for every 10 shares held [1] - Of the newly issued shares, 76,297,971 shares will be distributed to all shareholders based on their holdings, with 24,881,142 shares allocated to the controlling shareholder and former controlling shareholders being withheld to address related guarantee issues [1] - The remaining 948,215,003 shares will not be distributed to shareholders, with 861,696,863 shares designated for attracting restructuring investors and 86,518,140 shares allocated for settling outstanding debts [1]

证券代码：000615 证券简称：*ST美谷 公告编号：2025-101 奥园美谷科技股份有限公司 关于召开第一次债权人会议通知暨重整进展的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、重整的基本情况 会议登录测试：债权人在 2025 年 11 月 28 日，会收到发送短信通知的账号 和密码，参会人员可自行选择使用电脑或者手机参会。为确保会议当天顺利参 会，请收到账号和密码后务必登录会议进行测试，电脑端需要凭账号密码登录 "e 破通网络会议系统"（https://ept.jiulaw.cn）点击【进入测试】，进行 1 会议测试、查看会议文档。手机端需要搜索"e 破通网络会议"微信小程序，点 击【前去参会】，输入账号密码登录并进行会议测试。测试成功后请勿随意更 换参会设备和网络。网络会议平台使用问题，如无法登录等，请拨打 400 运维 电话（400 运维电话：400-810-1866，根据语音导航选择 3"律师/当事人的互 联网产品"，再选择 5"e 破通网络会议"，进行咨询）。 2025 年 11 月 14 日，湖北省襄阳市中级人民法院（以下简称" ...

奥园美谷科技股份有限公司 重整计划 （草案） $$\Xi\,{\bf O}\,{\bf\tilde{=}}\,\,\,\Xi\,\,{\bf\tilde{\mp}}\,{\bf\tilde{+}}\,{\bf\tilde{-}}\,{\bf\tilde{\tilde{\jmath}}}\,{\bf\tilde{\tilde{\jmath}}}$$ | | | | | | 释 义 除非本重整计划草案中另有明确所指，下列词语的含义为： | 简称 | | 词语含义或全称 | | --- | --- | --- | | 奥园美谷/债务人/ | 指 | 奥园美谷科技股份有限公司 | | 公司 | | | | 襄阳中院 | 指 | 襄阳市中级人民法院 | | 临时管理人 | 指 | 由襄阳中院指定的奥园美谷科技股份有限公司预重 | | | | 整期间的临时管理人 | | 管理人 | 指 | 由襄阳中院指定的奥园美谷科技股份有限公司管理 | | | 人 | | | 奥园科星/控股股 | 指 | 深圳奥园科星投资有限公司 | | 东 | | | | 中国奥园 | 指 | 中国奥园集团股份有限公司 | | 京汉控股/前任控 | ...

奥园美谷科技股份有限公司 重整计划（草案）之出资人权益调整方案 一、出资人权益调整的必要性 奥园美谷科技股份有限公司（以下简称"奥园美谷"或"公司"） 目前已不能清偿到期债务，明显缺乏清偿能力，陷入经营和财务危机， 如果奥园美谷进行破产清算，现有资产在清偿各类债权后已无剩余财 产向出资人分配，出资人权益将为零。为挽救奥园美谷，避免其破产 清算，出资人和债权人需共同做出努力，共同分担公司重整重生的成 本，因此需要对奥园美谷出资人的权益进行调整。 二、出资人权益调整的范围 根据《中华人民共和国企业破产法》第八十五条第二款规定，重 整计划草案涉及出资人权益调整事项的，应当设出资人组，对该事项 进行表决。 奥园美谷出资人组由截至出资人组会议之股权登记日在中国证 券登记结算有限责任公司深圳分公司（以下简称"中证登深圳分公 司"）登记在册的奥园美谷全体股东组成，除《奥园美谷科技股份有 限公司重整计划（草案）》（以下简称"重整计划草案"）另有规定 外，上述股东在出资人组会议之股权登记日后至出资人权益调整方案 实施完毕前，由于交易或非交易原因导致持股情况发生变动的，出资 人权益调整方案的效力及于其股票的受让方及/或承继方。 ...